AKT1 and pancreatic neoplasm: As shown in Fig. 7A, KRB-456 mouse treatment decreased the levels of P-MEK, P-AKT, and P-S6 but not P-ERK (see Discussion) in the pancreatic cancer PDX G160 in vivo.